Biomarkers predictive of endocrine resistance in breast cancer
The present invention is based on the identification of novel biomarkers predictive of endocrine resistance in breast cancer.
1. A method of treating a subject afflicted with a c-Src tyrosine kinase (CSK)-null breast cancer that is resistant to an endocrine therapy comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of PAK2 that directly binds PAK2, thereby treating the subject afflicted with the breast cancer that is resistant to the endocrine therapy.
2. The method of claim 1 , wherein the small molecule inhibitor of PAK2 reduces the number of proliferating cells in the cancer reduces the volume or size of a tumor of the cancer.
3. The method of claim 1 , wherein the small molecule inhibitor of PAK2 is administered in a pharmaceutically acceptable formulation.
4. The method of claim 1 , wherein the small molecule inhibitor of PAK2 is FRAX597.
5. The method of claim 1 , further comprising administering to the subject a therapeutic agent or regimen for treating the cancer.
6. The method of any one of claim 1 - 5 , wherein the cancer is an estrogen receptor positive (ER + ) breast cancer.
7. The method of any one of claims 1 - 5 , wherein the subject is an animal or mouse model of ER + breast cancer.
8. The method of any one of claims 1 - 5 , wherein the subject is a mammal.
9. The method of claim 8 , wherein the mammal is a mouse or a human.
10. The method of claim 6 , wherein the subject is a mammal.
11. The method of claim 10 , wherein the mammal is a mouse or a human.